Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial

Bengt Fellström(Uppsala University Hospital), Jonathan Barratt(University of Leicester), H. Terence Cook, Rosanna Coppo(Fondazione Ricerca Molinette), John Feehally(University of Leicester), Johan W. de Fijter(Leiden University Medical Center), Jürgen Floege(RWTH Aachen University), Gerd R. Hetzel(Heinrich Heine University Düsseldorf), Alan G. Jardine(University of Glasgow), Francesco Locatelli(Alessandro Manzoni Hospital), Bart Maes(AZ Delta), Alex Mercer(Pharmalink (Sweden)), Fernanda Ortiz(Helsinki University Hospital), Manuel Praga(Research Institute Hospital 12 de Octubre), Søren Schwartz Sørensen(Rigshospitalet), Vladimı́r Tesař(Charles University), Lucia Del Vecchio(Alessandro Manzoni Hospital)
The Lancet
March 28, 2017
Cited by 398Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis